Oncogene-induced senescence and its role in tumor suppression

Journal of Mammary Gland Biology and Neoplasia

Volumn 16, Issue 3, 2011, Pages 247-256

  Reddy, Jay P ^a   Li, Yi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anticancer barrier; Breast cancer; DDR; Oncogene induced senescence; Senescence

Indexed keywords

DOXYCYCLINE; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P16; PROTEIN P19; PROTEIN P21; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE INDUCED SENESCENCE; PRECANCER; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL AGING; HUMANS; NEOPLASMS; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 80053568722     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-011-9221-5     Document Type: Article

References (93)

1. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729-40. (Pubitemid 47312822)
2. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
3. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349-52. (Pubitemid 28063364)
4. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-60.
5. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res. 2006;66(6):2881-4.
6. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10(1):51-7.
7. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer. 2006;6(6):472-6.
8. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363-7.
9. Lee BY, Han JA, Im JS, et al. Senescence-associated betagalactosidase is lysosomal beta-galactosidase. Aging Cell. 2006;5(2):187-95.
10. Cristofalo VJ. SA beta Gal staining: biomarker or delusion. Exp Gerontol. 2005;40(10):836-8. (Pubitemid 41416547)
11. Yang NC, Hu ML. The limitations and validities of senescence associated-beta-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells. Exp Gerontol. 2005;40(10):813-9.
12. Wei W, Sedivy JM. Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. Exp Cell Res. 1999;253(2):519-22. (Pubitemid 30003113)
13. Kuilman T, Michaloglou C, Mooi WJ, et al. The essence of senescence. Genes Dev. 2010;24(22):2463-79.
14. Reddy JP, Peddibhotla S, Bu W, et al. Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc Natl Acad Sci U S A. 2010;107:3728-33.
15. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703-16. (Pubitemid 36724935)
16. Narita M, Krizhanovsky V, Nunez S, et al. A novel role for highmobility group a proteins in cellular senescence and heterochromatin formation. Cell. 2006;126(3):503-14. (Pubitemid 44163608)
17. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005;436(7051):642. (Pubitemid 41117258)
18. Sarkisian CJ, Keister BA, Stairs DB, et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9(5):493-505. (Pubitemid 46696530)
19. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432(7015):307-15. (Pubitemid 39551658)
20. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426(6963):194-8. (Pubitemid 37442589)
21. Herbig U, Jobling WA, Chen BP, et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21 (CIP1), but not p16 (INK4a). Mol Cell. 2004;14(4):501-13. (Pubitemid 38648803)
22. Harper JW, Elledge SJ. The DNA damage response: 10 years after. Mol Cell. 2007;28(5):739-45.
23. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26(56):7773-9. (Pubitemid 350242463)
24. Kastan MB. DNA damage responses: mechanisms and roles in human disease: 2007 G. H. A. Clowes memorial award lecture. Mol Cancer Res. 2008;6(4):517-24. (Pubitemid 351521833)
25. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512-22. (Pubitemid 351881854)
26. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316-23. (Pubitemid 39551659)
27. Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med. 2010;16(11):528-36.
28. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature. 2006;444(7119):638-42. (Pubitemid 44864443)
29. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444(7119):633-7. (Pubitemid 44864442)
30. Di Micco R, Sulli G, Dobreva M, et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol. 2011;13(3):292-302.
31. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593-602. (Pubitemid 27152402)
32. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37(5):961-76. (Pubitemid 40311739)
33. Sharpless NE, Ramsey MR, Balasubramanian P, et al. The differential impact of p16 (INK4a) or p19 (ARF) deficiency on cell growth and tumorigenesis. Oncogene. 2004;23(2):379-85. (Pubitemid 38174991)
34. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature. 1998;395(6698):125-6. (Pubitemid 28425643)
35. Evan GI, d'Adda di Fagagna F. Cellular senescence: hot or what? Curr Opin Genet Dev. 2009;19:25-31.
36. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91(5):649-59. (Pubitemid 27513656)
37. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720-4. (Pubitemid 41117276)
38. Packer L, Fuehr K. Low oxygen concentration extends the lifespan of cultured human diploid cells. Nature. 1977;267(5610):423-5. (Pubitemid 8105518)
39. Parrinello S, Samper E, Krtolica A, et al. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol. 2003;5(8):741-7. (Pubitemid 36986782)
40. Lu T, Finkel T. Free radicals and senescence. Exp Cell Res. 2008;314(9):1918-22.
41. Lee AC, Fenster BE, Ito H, et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem. 1999;274(12):7936-40.
42. Passos JF, Nelson G, Wang C, et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol. 2010;6:347.
43. Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science. 2010;330(6003):517-21.
44. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853-68.
45. McDuff FK, Turner SD. Jailbreak: oncogene-induced senescence and its evasion. Cell Signal. 2011;23(1):6-13.
46. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009;9(2):81-94.
47. Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132(3):363-74. (Pubitemid 351191995)
48. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133(6):1019-31. (Pubitemid 351787746)
49. Acosta JC, O'Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133(6):1006-18. (Pubitemid 351795610)
50. Cichowski K, Hahn WC. Unexpected pieces to the senescence puzzle. Cell. 2008;133(6):958-61. (Pubitemid 351787750)
51. Rodier F, Coppe JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973-9.
52. Dilley TK, Bowden GT, Chen QM. Novel mechanisms of sublethal oxidant toxicity: induction of premature senescence in human fibroblasts confers tumor promoter activity. Exp Cell Res. 2003;290(1):38-48. (Pubitemid 37153249)
53. Krtolica A, Parrinello S, Lockett S, et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001;98(21):12072-7. (Pubitemid 32959828)
54. Yang G, Rosen DG, Zhang Z, et al. The chemokine growthregulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A. 2006;103(44):16472-7. (Pubitemid 44715220)
55. Parrinello S, Coppe JP, Krtolica A, et al. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118(Pt 3):485-96. (Pubitemid 40310116)
56. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
57. Acosta JC, Gil J. A role for CXCR2 in senescence, but what about in cancer? Cancer Res. 2009;69(6):2167-70.
58. Lin AW, Barradas M, Stone JC, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998;12(19):3008-19. (Pubitemid 28469303)
59. Zhu J, Woods D, McMahon M, et al. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998;12(19):2997-3007. (Pubitemid 28469302)
60. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003;4(2):111-20. (Pubitemid 37040827)
61. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436(7051):660-5. (Pubitemid 41117262)
62. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725-30. (Pubitemid 41117277)
63. Lazzerini Denchi E, Attwooll C, Pasini D, et al. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol. 2005;25(7):2660-72. (Pubitemid 40381630)
64. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15(4):294-303.
65. Chen X, Mitsutake N, LaPerle K, et al. Endogenous expression of Hras (G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A. 2009;106(19):7979-84.
66. Yamakoshi K, Takahashi A, Hirota F, et al. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J Cell Biol. 2009;186(3):393-407.
67. Sun P, Yoshizuka N, New L, et al. PRAK is essential for rasinduced senescence and tumor suppression. Cell. 2007;128(2):295-308. (Pubitemid 46123511)
68. Goel VK, Ibrahim N, Jiang G, et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene. 2009;28(23):2289-98.
69. Dankort D, Filenova E, Collado M, et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007;21(4):379-84.
70. Mo L, Zheng X, Huang HY, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest. 2007;117(2):314-25. (Pubitemid 46203960)
71. Swarbrick A, Roy E, Allen T, et al. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci U S A. 2008;105(14):5402-7. (Pubitemid 351753875)
72. Majumder PK, Grisanzio C, O'Connell F, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008;14(2):146-55.
73. Nardella C, Chen Z, Salmena L, et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 2008;22(16):2172-7.
74. Xu M, Yu Q, Subrahmanyam R, et al. Beta-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo. Mol Cell Biol. 2008;28(5):1713-23.
75. Young AP, Schlisio S, Minamishima YA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008;10(3):361-9. (Pubitemid 351331024)
76. Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009;11(9):1135-42.
77. Courtois-Cox S, Genther Williams SM, Reczek EE, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 2006;10(6):459-72. (Pubitemid 44872980)
78. Trost TM, Lausch EU, Fees SA, et al. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res. 2005;65(3):840-9. (Pubitemid 40216443)
79. Zhang D, Shimizu T, Araki N, et al. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice. Oncogene. 2008;27(31):4305-14. (Pubitemid 352010006)
80. Reddy JP, Li Y. The RCAS-TVA system for introduction of oncogenes into selected somatic mammary epithelial cells in vivo. J Mammary Gland Biol Neoplasia. 2009
81. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell. 2007;12(5):479-91. (Pubitemid 350046408)
82. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627-37.
83. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128):661-5. (Pubitemid 46232887)
84. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656-60. (Pubitemid 46232886)
85. Sebastian T, Malik R, Thomas S, et al. C/EBPbeta cooperates with RB:E2F to implement Ras (V12)-induced cellular senescence. EMBO J. 2005;24(18):3301-12. (Pubitemid 41348704)
86. Atwood AA, Sealy L. Regulation of C/EBPbeta1 by Ras in mammary epithelial cells and the role of C/EBPbeta1 in oncogene-induced senescence. Oncogene. 2010;29(45):6004-15.
87. Arnal-Estape A, Tarragona M, Morales M, et al. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res. 2010;70(23):9927-36.
88. Wang X, Wong SC, Pan J, et al. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res. 1998;58(22):5019-22. (Pubitemid 28521151)
89. te Poele RH, Okorokov AL, Jardine L, et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62(6):1876-83. (Pubitemid 34408516)
90. Chang BD, Xuan Y, Broude EV, et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 1999;18(34):4808-18. (Pubitemid 29423564)
91. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109(3):335-46. (Pubitemid 34606876)
92. Roberson RS, Kussick SJ, Vallieres E, et al. Escape from therapyinduced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005;65(7):2795-803. (Pubitemid 40490082)
93. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63(11):2705-15. (Pubitemid 36667137)